Clinical Trial Update: Long-term Safety Study for GSK573719/GW642444 in Japanese [Phase 3]

View source ↗

Summary

A long-term safety study of the COPD drug GSK573719/GW642444 in Japanese patients has completed Phase 3, and results were posted in March 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK573719/GW642444 (GSK573719)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2014-03-14